Sacituzumab govitecan activity in advanced breast cancer

The Lancet. Oncology

Volumn 18, Issue 5, 2017, Pages e246-

  Burki, Talha Khan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CAMPTOTHECIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; SACITUZUMAB GOVITECAN;

ANALOGS AND DERIVATIVES; FEMALE; HUMAN; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; IMMUNOCONJUGATES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85036565752     PISSN: None     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30232-2     Document Type: Note

References (0)